-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, leading traditional pharmaceutical companies have begun to pay attention to "License in" and actively participate in innovation competition through licensing transactions one after another
.
For example, Hengrui Medicine will aggressively buy new drugs in 2021
.
First, it spent 1.
4 billion yuan to introduce Dalian Wanchun Brin's first-in-class new drug GEF-H1 activator punabulin, and then with 30 million US dollars, obtained Tianguangshi's third-generation CD20 monoclonal antibody MIL62 in China.
Exclusive commercialization rights
.
In November, Hengrui introduced CStone's anti-tumor drug CTLA-4 monoclonal antibody for about 1.
3 billion yuan
.
As the country vigorously promotes the development of innovative industries, domestic pharmaceutical innovation companies have begun to increase.
In addition to Hengrui Pharmaceuticals, many large domestic pharmaceutical companies such as Qilu Pharmaceuticals, Hansoh Pharmaceuticals, and Kexing Pharmaceuticals are also actively participating in the introduction of innovative drugs
.
Since the beginning of this year, many domestic pharmaceutical companies have introduced a variety of new foreign drugs through "License in" to enhance their innovation capabilities
.
For example, on February 22, Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical signed an exclusive product license agreement with Kiniksa, a wholly-owned subsidiary of Kiniksa Pharmaceuticals, Ltd.
in the United States.
Zhongmei Huadong obtained two autoimmune products from Kiniksa.
The exclusive license of Arcalyst and Mavrilimumab, the global innovative products in the field, in 24 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia, New Zealand, and India, including development, registration and commercialization rights
.
According to the announcement, Sino-US Huadong will pay Kiniksa an upfront payment of US$22 million, development, registration and sales milestone payments of up to US$640 million, as well as tiered double-digit royalties on net sales
.
In addition, on January 4, Shufang Pharmaceutical and Santhera Pharmaceuticals also announced that they had reached an exclusive license agreement for the new rare disease drug Vamorolone
.
The agreement shows that Shufang Pharma has obtained exclusive rights to develop and commercialize Vamorolone in Greater China for Duchenne muscular dystrophy and other rare disease indications
.
The former will pay an upfront payment in the tens of millions of dollars and milestone payments related to U.
S.
registration filings, totaling $20 million
.
In addition, double-digit percentage royalties will be paid
.
In general, according to the current domestic emphasis on innovative drugs, it will become more and more common for leading pharmaceutical companies to adopt the license in model
.
However, it should be noted that a large number of Chinese pharmaceutical companies are currently seeking to innovate through license-in, which is also causing some new drawbacks
.
First of all, the cost of introducing innovative drugs from overseas is getting higher and higher, which can be seen from the fact that the transaction amount of domestic pharmaceutical companies is still breaking through
.
Secondly, the homogenization competition of domestic innovative drugs is becoming more and more serious
.
It is understood that, in recent years, the more popular CAR-T cell therapy products, the targets of CAR-T projects currently under clinical research are mainly concentrated on CD19, CD20, CD22, GPC3, BCMA and other popular targets; among them, CD19 The proportion of targeted CAR-T clinical trials exceeds 40%
.
In this regard, analysts believe that the future innovation of pharmaceutical companies cannot completely rely on the "License in" model, but still needs to have a high level of technology themselves, and accelerate through independent innovation to rush out of the current me-too, me-better, biosimilar, Fast follow dilemma, the transition from license in to license out, can continuously improve competitiveness
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
For example, Hengrui Medicine will aggressively buy new drugs in 2021
.
First, it spent 1.
4 billion yuan to introduce Dalian Wanchun Brin's first-in-class new drug GEF-H1 activator punabulin, and then with 30 million US dollars, obtained Tianguangshi's third-generation CD20 monoclonal antibody MIL62 in China.
Exclusive commercialization rights
.
In November, Hengrui introduced CStone's anti-tumor drug CTLA-4 monoclonal antibody for about 1.
3 billion yuan
.
As the country vigorously promotes the development of innovative industries, domestic pharmaceutical innovation companies have begun to increase.
In addition to Hengrui Pharmaceuticals, many large domestic pharmaceutical companies such as Qilu Pharmaceuticals, Hansoh Pharmaceuticals, and Kexing Pharmaceuticals are also actively participating in the introduction of innovative drugs
.
Since the beginning of this year, many domestic pharmaceutical companies have introduced a variety of new foreign drugs through "License in" to enhance their innovation capabilities
.
For example, on February 22, Huadong Medicine announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical signed an exclusive product license agreement with Kiniksa, a wholly-owned subsidiary of Kiniksa Pharmaceuticals, Ltd.
in the United States.
Zhongmei Huadong obtained two autoimmune products from Kiniksa.
The exclusive license of Arcalyst and Mavrilimumab, the global innovative products in the field, in 24 Asia-Pacific countries and regions (excluding Japan) including China, South Korea, Australia, New Zealand, and India, including development, registration and commercialization rights
.
According to the announcement, Sino-US Huadong will pay Kiniksa an upfront payment of US$22 million, development, registration and sales milestone payments of up to US$640 million, as well as tiered double-digit royalties on net sales
.
In addition, on January 4, Shufang Pharmaceutical and Santhera Pharmaceuticals also announced that they had reached an exclusive license agreement for the new rare disease drug Vamorolone
.
The agreement shows that Shufang Pharma has obtained exclusive rights to develop and commercialize Vamorolone in Greater China for Duchenne muscular dystrophy and other rare disease indications
.
The former will pay an upfront payment in the tens of millions of dollars and milestone payments related to U.
S.
registration filings, totaling $20 million
.
In addition, double-digit percentage royalties will be paid
.
In general, according to the current domestic emphasis on innovative drugs, it will become more and more common for leading pharmaceutical companies to adopt the license in model
.
However, it should be noted that a large number of Chinese pharmaceutical companies are currently seeking to innovate through license-in, which is also causing some new drawbacks
.
First of all, the cost of introducing innovative drugs from overseas is getting higher and higher, which can be seen from the fact that the transaction amount of domestic pharmaceutical companies is still breaking through
.
Secondly, the homogenization competition of domestic innovative drugs is becoming more and more serious
.
It is understood that, in recent years, the more popular CAR-T cell therapy products, the targets of CAR-T projects currently under clinical research are mainly concentrated on CD19, CD20, CD22, GPC3, BCMA and other popular targets; among them, CD19 The proportion of targeted CAR-T clinical trials exceeds 40%
.
In this regard, analysts believe that the future innovation of pharmaceutical companies cannot completely rely on the "License in" model, but still needs to have a high level of technology themselves, and accelerate through independent innovation to rush out of the current me-too, me-better, biosimilar, Fast follow dilemma, the transition from license in to license out, can continuously improve competitiveness
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
